Síndrome metabólico: revisión de la literatura

Palabras clave: síndrome metabólico, diabetes mellitus 2, dislipidemia, resistencia a la insulina, obesidad.

Resumen

El síndrome metabólico es una condición clínica que incluye un conjuntode anomalías cardiometabólicas como hipertensión arterial, obesidad central, resistencia a la insulina y dislipidemia aterogénica. La prevalencia del síndrome metabólico se ha incrementado en los últimos años en el mundo, representando un problema de salud pública, porque aumenta directamente entre dos y seis veces el riesgo de enfermedades cardiovasculares y diabetes mellitus tipo 2. Los cambios en el estilo de vida pueden revertir los componentes del síndrome metabólico, pero en ocasiones es necesaria la intervención farmacológica para un control más estricto de los factores de riesgo. Este artículo tiene como objetivo explicar de forma clara y precisa los aspectos generales del síndrome metabólico en adultos.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

María Carolina Fragozo-Ramos, Universidad de Antioquia

Médica, Especialista en Medicina Interna, Residente de Endocrinología Clínica y Metabolismo, Facultad de Medicina, Universidad de Antioquia. Medellín, Colombia. https://orcid.org/0000-0002-6657-9989.

Referencias bibliográficas

Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13. https://doi.org/10.2337/dc06-1414.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645. https://doi.org/10.1161/circulationaha.109.192644.

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034.

McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-390. https://doi.org/10.2337/diacare.28.2.385.

Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Sr., Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007;30:1219-1225. https://doi.org/10.2337/dc06-2484.

Suárez-Ortegón MF, Arbeláez A, Mosquera M, Méndez F, Pradilla A, Aguilar-de Plata C. Association of self-reported familial history of cardiometabolic disease with metabolic syndrome in apparently healthy urban Colombian men. Am J Hum Biol 2013;25:228-230. https://doi.org/10.1002/ajhb.22371.

Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461. https://doi.org/10.1126/science.1103160.

Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60:S19-24.

Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-1346. https://doi.org/10.1016/j.clinbiochem.2009.05.018.

Sookoian S, Pirola CJ. Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep 2011;13:149-157. https://doi.org/10.1007/s11906-010-0164-9.

Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-288. https://doi.org/10.1161/01.cir.0000019884.36724.d9.

Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis 2015;14:121. https://doi.org/10.1186/s12944-015-0123-1.

Grundy SM. Adipose tissue and metabolic syndrome: too much, too little or neither. Eur J Clin Invest 2015;45:1209-1217. https://doi.org/10.1111/eci.12519.

Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008;37:635-646. https://doi.org/10.1016/j.ecl.2008.06.007.

Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014;40:16-28. https://doi.org/10.1016/j.diabet.2013.08.002.

Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636. https://doi.org/10.1161/atvbaha.107.151092.

Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab 2020;34:27-42. https://doi.org/10.1016/j.molmet.2019.12.014.

Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. Jama 2015;313:1973-1974. https://doi.org/10.1001/jama.2015.4260.

Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004;27:2444-2449. https://doi.org/10.2337/diacare.27.10.2444.

Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. Jama 2020;323:2526-2528. https://doi.org/10.1001/jama.2020.4501.

Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández-Ballart JD, Salas-Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr 2011;14:1702-1713. https://doi.org/10.1017/s1368980010003320.

Ramírez-Vélez R, Correa-Bautista JE, Sanders-Tordecilla A, Ojeda-Pardo ML, Cobo-Mejía EA, Castellanos-Vega RD, et al. Percentage of body fat and fat mass index as a screening tool for metabolic syndrome prediction in Colombian university students. Nutrients 2017;9:1009. https://doi.org/10.3390/nu9091009.

Davila EP, Quintero MA, Orrego ML, Ford ES, Walke H, Arenas MM, et al. Prevalence and risk factors for metabolic syndrome in Medellin and surrounding municipalities, Colombia, 2008-2010. Prev Med 2013;56:30-34. https://doi.org/10.1016/j.ypmed.2012.10.027.

Higuita-Gutiérrez LF, Martínez-Quiroz WJ, Cardona-Arias JA. Prevalence of metabolic syndrome and its association with sociodemographic characteristics in participants of a public chronic disease control program in Medellin, Colombia, in 2018. Diabetes Metab Syndr Obes 2020;13:1161-1169. https://doi.org/10.2147/dmso.S242826.

Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest 2019;129:4009-4021. https://doi.org/10.1172/jci129190.

Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48. https://doi.org/10.1161/circulationaha.106.675355.

Suiter C, Singha SK, Khalili R, Shariat-Madar Z. Free fatty acids: Circulating contributors of metabolic syndrome. Cardiovasc Hematol Agents Med Chem 2018;16:20-34. https://doi.org/10.2174/1871525716666180528100002.

Žák A, Burda M, Vecka M, Zeman M, Tvrzická E, Staňková B. Fatty acid composition indicates two types of metabolic syndrome independent of clinical and laboratory parameters. Physiol Res 2014;63:S375-385. https://doi.org/10.33549/physiolres.932868.

Dai L, Gonçalves CM, Lin Z, Huang J, Lu H, Yi L, et al. Exploring metabolic syndrome serum free fatty acid profiles based on GC-SIM-MS combined with random forests and canonical correlation analysis. Talanta 2015;135:108-114. https://doi.org/10.1016/j.talanta.2014.12.039.

Fathi-Dizaji B. The investigations of genetic determinants of the metabolic syndrome. Diabetes Metab Syndr 2018;12:783-789. https://doi.org/10.1016/j.dsx.2018.04.009.

Carson C, Lawson HA. Epigenetics of metabolic syndrome. Physiol Genomics 2018;50:947-955. https://doi.org/10.1152/physiolgenomics.00072.2018.

Kuneš J, Vaněčková I, Mikulášková B, Behuliak M, Maletínská L, Zicha J. Epigenetics and a new look on metabolic syndrome. Physiol Res 2015;64:611-620. https://doi.org/10.33549/physiolres.933174.

Takahara M, Shimomura I. Metabolic syndrome and lifestyle modification. Rev Endocr Metab Disord 2014;15:317-327. https://doi.org/10.1007/s11154-014-9294-8.

Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005;81:358-366. https://doi.org/10.1136/pgmj.2004.025601.

Iqbal J, Al Qarni A, Hawwari A, Alghanem AF, Ahmed G. Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Curr Diabetes Rev 2018;14:427-433. https://doi.org/10.2174/1573399813666170705161039.

Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis 2017;11:215-225. https://doi.org/10.1177/1753944717711379.

Turpin SM, Ryall JG, Southgate R, Darby I, Hevener AL, Febbraio MA, et al. Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice. J Physiol 2009;587:1593-1605. https://doi.org/10.1113/jphysiol.2008.166033.

Adams JM, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004;53:25-31. https://doi.org/10.2337/diabetes.53.1.25.

Perry RJ, Camporez JG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 2015;160:745-758. https://doi.org/10.1016/j.cell.2015.01.012.

Neuhauser HK. The metabolic syndrome. Lancet 2005;366:1922-1924. https://doi.org/10.1016/s0140-6736(05)67780-x.

Aschner P, Buendía R, Brajkovich I, Gonzalez A, Figueredo R, Juarez XE, et al. Determination of the cutoff point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Res Clin Pract 2011;93:243-247. https://doi.org/10.1016/j.diabres.2011.05.002.

Prado CM, Siervo M, Mire E, Heymsfield SB, Stephan BC, Broyles S, et al. A population-based approach to define body-composition phenotypes. Am J Clin Nutr 2014;99:1369-1377. https://doi.org/10.3945/ajcn.113.078576.

Shea JL, King MT, Yi Y, Gulliver W, Sun G. Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutr Metab Cardiovasc Dis 2012;22:741-747. https://doi.org/10.1016/j.numecd.2010.11.009.

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020;395:795-808. https://doi.org/10.1016/s0140-6736(19)32008-2.

Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007;25:909-920. https://doi.org/10.1097/HJH.0b013e328048d004.

Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013;62:569-576. https://doi.org/10.1016/j.jacc.2013.05.045.

Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 2007;44:232-263. https://doi.org/10.1258/000456307780480963.

Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004;22:1991-1998. https://doi.org/10.1097/00004872-200410000-00023.

Zhao F, Yang R, Maimaitiaili R, Tang J, Zhao S, Xiong J, et al. Cardiac, macro-, and micro-circulatory abnormalities in association with individual metabolic syndrome component: The northern shanghai study. Front Cardiovasc Med 2021;8:690521. https://doi.org/10.3389/fcvm.2021.690521.

Park JH, Kim BS, Ovbiagele B. Concomitant diabetes or hypertension with metabolic syndrome on the extent of intracranial atherosclerotic stenosis. Neurol Sci 2020;41:387-395. https://doi.org/10.1007/s10072-019-04105-w.

Xie K, Bao L, Jiang X, Ye Z, Bing J, Dong Y, et al. The association of metabolic syndrome components and chronic kidney disease in patients with hypertension. Lipids Health Dis 2019;18:229. https://doi.org/10.1186/s12944-019-1121-5.

Batista TM, Haider N, Kahn CR. Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia 2021;64:994-1006. https://doi.org/10.1007/s00125-021-05415-5.

López-Jaramillo P, Calderón C, Castillo J, Escobar ID, Melgarejo E, Parra GA. Prediabetes in Colombia: Expert consensus. Colomb Med 2017;48:191-203. https://doi.org/10.25100/cm.v43i4.3662.

Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab 2014;99:1983-1992. https://doi.org/10.1210/jc.2014-1425.

American Diabetes Association (ADA). 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15-33. https://doi.org/10.2337/dc21-S002.

Bi X, Yeo PL, Loo YT, Henry CJ. Associations between circulating fatty acid levels and metabolic risk factors. J Nutr Intermed Metab 2019;15:65-69. https://doi.org/https://doi.org/10.1016/j.jnim.2019.02.002.

Lu Y, Wang Y, Ong CN, Subramaniam T, Choi HW, Yuan JM, et al. Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS. Diabetologia 2016;59:2349-2359. https://doi.org/10.1007/s00125-016-4069-2.

Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 2020;35:100937. https://doi.org/10.1016/j.molmet.2020.01.001.

Yilmaz B, Vellanki P, Ata B, Yildiz BO. Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 2018;109:356-364. https://doi.org/10.1016/j.fertnstert.2017.10.018.

Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: A large Canadian cohort. J Obstet Gynaecol Can 2019;41:1453-1460. https://doi.org/10.1016/j.jogc.2018.11.026.

Meyer ML, Sotres-Alvarez D, Steiner AZ, Cousins L, Talavera GA, Cai J, et al. Polycystic ovary syndrome signs and metabolic syndrome in premenopausal Hispanic/Latina women: The HCHS/SOL study. J Clin Endocrinol Metab 2020;105:e447-456. https://doi.org/10.1210/clinem/dgaa012.

Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017;15:45. https://doi.org/10.1186/s12916-017-0806-8.

Castro-Martínez MG, Banderas-Lares DZ, Ramírez-Martínez JC, Escobedo-de la Peña J. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir 2012;80:128-133.

Caballería L, Pera G, Rodríguez L, Auladell MA, Bernad J, Canut S, et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol 2012;24:1007-1011. https://doi.org/10.1097/MEG.0b013e328355b87f.

Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012;107:1852-1858. https://doi.org/10.1038/ajg.2012.314.

Swarup S, Goyal A, Grigorova Y, et al. Metabolic Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Acceso 12 de agosto de 2021. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK459248/.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553. https://doi.org/10.1002/(sici)1096-9136(199807)15:7<539::Aid-dia668>3.0.Co;2-s.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Jama 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486.

Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443. https://doi.org/10.1046/j.1464-5491.1999.00059.x.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x.

Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-252.

Ruiz ÁJ, Aschner PJ, Puerta MF, Cristancho RA. Estudio IDEA (International Day for Evaluation of Abdominal Obesity): prevalencia de obesidad abdominal y factores de riesgo asociados en atención primaria en Colombia. Biomédica 2012;32:610-616.

Gil JC, De Loredo L , Ramos DO, Lúquez H, Piña C, Bruce HG. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes ( ALAD ). Epidemiología, diagnóstico, control, prevención y tratamiento del síndrome metabólico en adultos. Rev ALAD 2010;18:25-44.

Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-1935. https://doi.org/10.1016/s0140-6736(08)60602-9.

Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31:1898-1904. https://doi.org/10.2337/dc08-0423.

Deen D. Metabolic syndrome: time for action. Am Fam Physician 2004;69:2875-2882.

Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20:12. https://doi.org/10.1007/s11906-018-0812-z.

Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004;24:e19-24. https://doi.org/10.1161/01.Atv.0000112379.88385.67.

Ryan NM, O'Donovan CB, Forster H, Woolhead C, Walsh MC. New tools for personalised nutrition: The Food4Me project. Nutr Bull 2015;40:134-139. https://doi.org/https://doi.org/10.1111/nbu.12143.

Masquio DC, de Piano-Ganen A, Oyama LM, Campos RM, Santamarina AB, de Souza GI, et al. The role of free fatty acids in the inflammatory and cardiometabolic profile in adolescents with metabolic syndrome engaged in interdisciplinary therapy. J Nutr Biochem 2016;33:136-144. https://doi.org/10.1016/j.jnutbio.2016.03.017.

Guerendiain M, Montes R, López-Belmonte G, Martín-Matillas M, Castellote AI, Martín-Bautista E, et al. Changes in plasma fatty acid composition are associated with improvements in obesity and related metabolic disorders: A therapeutic approach to overweight adolescents. Clin Nutr 2018;37:149-156. https://doi.org/10.1016/j.clnu.2016.11.006.

Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol 2015;763:64-74. https://doi.org/10.1016/j.ejphar.2015.03.093.

Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. Jama 2014;311:74-86. https://doi.org/10.1001/jama.2013.281361.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989. https://doi.org/10.1056/NEJMoa2032183.

Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021;384:1719-1730. https://doi.org/10.1056/NEJMoa2028198.

Dalle-Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures. Biopsychosoc Med 2020;14:5. https://doi.org/10.1186/s13030-020-00177-9.

Demirbas N, Kutlu R, Kurnaz A. The relationship between mindful eating and body mass index and body compositions in adults. Ann Nutr Metab 2021:77:262-270. https://doi.org/10.1159/000518675.

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med 2016;26:364-373. https://doi.org/10.1016/j.tcm.2015.10.004.

Cómo citar
1.
Fragozo-Ramos MC. Síndrome metabólico: revisión de la literatura. Med. Lab. [Internet]. 11 de enero de 2022 [citado 4 de octubre de 2022];26(1):47-62. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/559
Publicado
2022-01-11
Sección
Artículos de revisión
Crossref Cited-by logo